Fallarero Adyary, Hanski Leena, Vuorela Pia
Division of Pharmaceutical Biosciences, Centre for Drug Research, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Planta Med. 2014 Sep;80(14):1182-99. doi: 10.1055/s-0034-1383061. Epub 2014 Sep 15.
Natural product sources have been a valuable provider of molecular diversity in many drug discovery programs and several therapeutically important drugs have been isolated from these. However, the screening of such materials can be very complicated due to the fact that they contain a complex mixture of secondary metabolites, but also the purified natural compounds exert a challenge for bioactivity screening. Success in identifying new therapeutics using in vitro bioassays is largely dependent upon the proper design, validation, and implementation of the screening assay. In this review, we discuss some aspects which are of significant concern when screening natural products in a microtiter plate-based format, being partly applicable to other assay formats as well, such as validation parameters, layouts for assay protocols, and common interferences caused by natural products samples, as well as various troubleshooting strategies. Examples from the field of natural product drug discovery of antibacterial compounds are discussed, and contributions from the realm of academic screenings are highlighted.
在许多药物发现项目中,天然产物来源一直是分子多样性的重要提供者,并且已经从这些来源中分离出了几种具有重要治疗意义的药物。然而,由于这些材料含有次生代谢物的复杂混合物,对其进行筛选可能非常复杂,而且纯化的天然化合物也给生物活性筛选带来了挑战。使用体外生物测定法鉴定新疗法的成功很大程度上取决于筛选测定法的正确设计、验证和实施。在这篇综述中,我们讨论了在基于微量滴定板的形式筛选天然产物时一些值得关注的方面,这些方面部分也适用于其他测定形式,如验证参数、测定方案的布局、天然产物样品引起的常见干扰,以及各种故障排除策略。讨论了天然产物抗菌化合物药物发现领域的实例,并强调了学术筛选领域的贡献。